Table 1 Stem cell clinical trials in patients with chronic heart failure
From: Endpoints in stem cell trials in ischemic heart failure
Trial | N | Cell type | Delivery | Timing post-infarction | Primary endpoint |
|---|---|---|---|---|---|
MAGIC37 [39] | 97 | SM | Epicardial | >4Â weeks | No change LVEF |
Dib et al. [40] | 23 | SM | Endocardial | >10Â years | Improved LVEF and viability |
SEISMIC11 [12] | 47 | SM | Endocardial | Chronic | No change LVEF, improved 6-min walk distance at 6Â months |
TOPCARE-CHD [41] | 121 | BM-derived progenitor cells | Coronary | Chronic | Improved survival and decreased levels of NTproBNP and NTproANP in patients who received cells |
C-Cure20 [21] | 45 | Guided cardiopoietic BM-derived MSC | Endocardial | Ischemic cardiomyopathy | Safety/feasibility, improved LVEF by echo and 6-min walk distance |
FOCUS-CCTRN [42] | 92 | BMMNC | Endocardial | >30Â days | No changes in LVESV index and maximal oxygen consumption (VO2max) by SPECT |
POSEIDON [22] | 30 | MSC | Endocardial | >60Â days | No changes in LVEF by echo; improvement in 6-min walk test, MLHFQ in autologous group |
Poglajen et al. [43] | 33 | CD34+ | Endocardial | >6Â months | Increase in LVEF, 6-min walk distance and a decrease in NTproBNP |
SCIPIO [44] | 33 | c-kit + CSC | Coronary | >4 months after CABG | Increase in MRI LVEF after 4 and 12 months and decrease of infarct size after 4 and 12 months |
TAC-HFT23 [24] | 65 | BMMNC, MSC | Endocardial | Ischemic cardiomyopathy | Improved 6-min walk distance, regional myocardial function and decreased infarct size after 1Â year (MRI or CT) in MSC group, but not in BMMNC or placebo group |